526953

Standalone Revenue for Q4 FY26 was ₹259.01 Cr vs ₹196.74 Cr (▲31.65% YoY), EBITDA was ₹64.07 Cr vs ₹29.32 Cr (▲118.52% YoY), and PAT was ₹43.45 Cr vs ₹14.79 Cr (▲193.78% YoY). EBITDA Margin expanded to 24.73% from 14.90% (▲983bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for FY26.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.59% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY) for the quarter ended March 31, 2026. EBITDA Margin expanded to 24.73% vs 14.90% (▲983bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for the financial year 2025-26.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.74% vs 14.90% (▲984bps). The Board also recommended a final dividend of ₹10 (100%) per equity share for FY2025-26.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.73% vs 14.90% (▲983bps). The Board also recommended a final dividend of ₹10/- per equity share (100%) for FY 2025-26, scheduled to be paid within 30 days of the 37th Annual General Meeting (August 20, 2026).

Consolidated Revenue ₹259.40Cr vs ₹197.66Cr (▲31.24% YoY), EBITDA ₹68.37Cr vs ₹35.77Cr (▲91.15% YoY), PAT ₹47.49Cr vs ₹21.00Cr (▲126.14% YoY). EBITDA Margin 26.36% vs 18.10% (▲826bps). The Board also recommended a final dividend of ₹10/- (100%) per equity share for FY 2025-26, subject to shareholder approval.

Standalone Revenue ₹259.01Cr vs ₹196.74Cr (▲31.65% YoY), EBITDA ₹64.07Cr vs ₹29.32Cr (▲118.52% YoY), PAT ₹43.45Cr vs ₹14.79Cr (▲193.78% YoY). EBITDA Margin 24.73% vs 14.90% (▲983bps). The board also recommended a final dividend of ₹10/- (100%) per equity share for FY 2025-26.

Venus Remedies Limited received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a specialty oncology therapy for autologous transplantation. This is the company's first global approval for Plerixafor and its first Marketing Authorization for a specialty oncology therapy, enabling commercialization in Saudi Arabia. This move advances the company's shift into higher-value specialty injectables in regulated markets, with the Saudi Arabian pharmaceutical market projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033.

Venus Remedies Limited informed the stock exchanges about social media communications made on its official handles (Instagram, Facebook, LinkedIn, and X) regarding awareness to shareholders for updation of KYC details with the company, as per Regulation 30 of SEBI (LODR) Regulations, 2015.